Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)

The Notice of Funding Opportunity (NOFO) from the National Cancer Institute (NCI), titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)," aims to support revision applications from currently funded NCI P50 specialized centers. The goal is to expand or accelerate ongoing research projects by integrating novel technologies or devices developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program. These awards are intended to facilitate the independent validation and adoption of emerging technologies, enhancing their utility within cancer research communities. The primary objectives include advancing strategies for cancer prevention, improving early detection and diagnostic tools, enhancing treatment outcomes, and reducing cancer-related morbidity and mortality. Funded projects should address critical gaps in knowledge, develop innovative tools, and demonstrate the practical application of IMAT-supported technologies in ongoing research studies. Applications must propose projects that significantly enhance the parent study’s goals while aligning with the IMAT program's focus on technological advancement. Eligible applicants are restricted to currently funded NCI P50 centers with at least one year remaining in their parent award, excluding no-cost extension periods. Applications must focus on technologies specifically developed under the IMAT program and must not include commercially available platforms. Proposals incorporating technologies developed by the parent award's principal investigator are also deemed non-responsive. Collaborative partnerships with IMAT technology developers are encouraged to maximize the translational potential of the proposed integration. The budget for this NOFO allows for up to $150,000 in direct costs per year for a project duration of up to two years, not exceeding the end date of the parent P50 award. Applications must include a well-structured revision project component that outlines specific aims, research strategies, and the anticipated impact of the incorporated technology. Proposals should include justification for how the technology will address existing limitations in the parent project and how its integration will benefit the broader cancer research community. The review process will assess the significance, innovation, and approach of the proposed revisions. Specific evaluation criteria include the importance of integrating IMAT-supported technologies, the potential to independently validate these technologies, and the feasibility of achieving the stated research objectives. Applications will also be reviewed for their approach to human subjects’ protections, inclusion of diverse populations, and adherence to NIH data-sharing requirements. Applicants must submit a letter of intent at least 30 days prior to the application deadline, detailing the project title, principal investigator(s), participating institutions, and a brief description of the proposed revision. Full applications must comply with NIH submission guidelines and are due by April 4, 2025, with subsequent deadlines on October 3, 2025. Interested parties are encouraged to contact the NCI program officials for guidance on the suitability of their proposed technologies and alignment with the NOFO's goals.